Sarah Lee, M.D. Hematology/Oncology Fellow at Cleveland Clinic Discusses The Future Of Daratumumab At The 60th ASH Annual Meeting on…
Browsing: Multiple Myeloma
Sarah Lee, M.D. Hematology/Oncology Fellow at Cleveland Clinic Discusses Daratumumab In A Primary Fractory Population At The 60th ASH Annual…
Rafael Fonseca, M.D. Clinical Investigator For The Damon Runyon Cancer Research Fund Discusses MAIA Study, AMG 420 Compound, KRD Transplant…
Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch…
Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch…
Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch…
Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch…
Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses Whats Next For Isatuximab At The 60th ASH Annual Meeting on…
Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses Value Of Dexamethasone At The 60th ASH Annual Meeting on Dec…
Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses Phase 2 Study Isatuximab & Dexamethasone At The 60th ASH Annual…
Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses ISA Combo: Velcade, Revlimid & Dexamethasone At The 60th ASH Annual…
Francesca Gay, MD, PhD of the GIMEMA, European Myeloma Network discusses the next steps for Ixazomib in Multiple Myeloma after…
Francesca Gay, MD, PhD of the GIMEMA, European Myeloma Network discusses Duration of Maintenance and the Advantage to High Risk…
Francesca Gay, MD, PhD of the GIMEMA, European Myeloma Network discusses the results of the phase 3 study TOURMALINE-MM3. The…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ken Anderson M.D., Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute…
Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr.…
Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr.…
Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr.…
Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr.…
Earn CME: https://naccme.com/program/7312 In this presentation from the ‘Looking for One in a Million: Is MRD the New Primary Goal…
Earn CME: https://naccme.com/program/7312 In this presentation from the ‘Looking for One in a Million: Is MRD the New Primary Goal…
In this weeks video, Dr. Brian G.M. Durie talks about ways myeloma patients, caregivers, or family members can give back…
In this weeks video, Dr. Brian G.M. Durie explains the results of the A.R.R.O.W. trial, which proved the efficacy and…
In this weeks video, Dr. Brian G.M. Durie discusses the Black Swan Research Initiatives 3 Cure trials, which use new…
In this weeks video, Dr. Brian G.M. Durie details the results of the STORM 2b trial, which uses selinexor in…
In this weeks video, Dr. Durie discusses the two main types of minimal residual disease (MRD) tests for multiple myeloma…
In this weeks video, Dr. Brian G.M. Durie comments on why it is not necessary for multiple myeloma patients to…
In this video, Dr. Brian G.M. Durie explains how researchers are studying minimal residual disease (MRD) testing further to better…
In this video, Dr. Brian G.M. Durie explains that active myeloma is diagnosed if a patient has CRAB features and…
Earn CME: https://naccme.com/program/7307 In this Key Insights activity, Drs. Morton Coleman and Ruben Niesvizky discuss myeloma presentation highlights from Lymphoma…
Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the current outlook of Waldenströms macroglobulinemia (WM), from…
Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, updates us at the European…
Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, presents exciting results from clinical…
Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, discusses the updated analysis of the CASTOR trial (NCT02136134)…
Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Jesús San…
Heinz Ludwig, MD, PhD, from Wilhelminen Cancer Research Institute, Vienna, Austria, discusses treatment sequencing in multiple myeloma (MM). Dr Ludwig…
Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Evangelos Terpos,…
Functional imaging techniques serve an essential role in diagnostics. Here, Elena Zamagni, MD, PhD, of the University of Bologna, Bologna,…
Annemiek Broyl, MD, PhD, from Erasmus Medical Center and University, Rotterdam, Netherlands, discusses how to treat high-risk multiple myeloma (MM).…
Alessandra Larocca, MD, PhD, of the University Hospital Città della Salute e della Scienza, Torino, Italy, discusses the importance of…
The mechanism for the previously unknown occurrence of thrombocytopenia and neutropenia in patients with myeloma treated with immunomodulatory drugs (IMiDs)…
Dr Suzanne Lentzsch, MD, PhD, of Columbia University, New York, NY, presents data from the latest clinical trials testing drugs…
Somatic mutations can be used to inform diagnosis and prognosis, but they are also useful targets for novel therapies. Valeria…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Meletios Dimopoulos, MD, of the University…